{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:32Z","timestamp":1792685972708,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-022-02139-9","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T21:03:02Z","timestamp":1649883782000},"page":"2292-2301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK"],"prefix":"10.1007","volume":"39","author":[{"given":"Julian D.","family":"Gillmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R. E.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"issue":"1","key":"2139_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6. https:\/\/doi.org\/10.1186\/s13023-017-0726-x.","journal-title":"Orphanet J Rare Dis"},{"key":"2139_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. https:\/\/doi.org\/10.1186\/1750-1172-8-31.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2139_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2139_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411\u201323. https:\/\/doi.org\/10.1002\/mus.20821.","journal-title":"Muscle Nerve"},{"issue":"5","key":"2139_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337. https:\/\/doi.org\/10.1002\/mus.26034.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2139_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139. https:\/\/doi.org\/10.1111\/jns.12153.","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"2139_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jcmg.2014.03.007","volume":"7","author":"E Arbustini","year":"2014","unstructured":"Arbustini E, Merlini G. Early identification of transthyretin-related hereditary cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):511\u20134. https:\/\/doi.org\/10.1016\/j.jcmg.2014.03.007.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"2139_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehr383.","journal-title":"Eur Heart J"},{"issue":"6","key":"2139_CR9","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109\u201322. https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"key":"2139_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323. https:\/\/doi.org\/10.2147\/TCRM.S219979.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2139_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","volume":"27","author":"C Lahuerta Pueyo","year":"2019","unstructured":"Lahuerta Pueyo C, Aibar Arregui MA, Gracia Gutierrez A, Bueno Juana E, Menao GS. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data. Eur J Hum Genet. 2019;27(5):783\u201391. https:\/\/doi.org\/10.1038\/s41431-019-0337-1.","journal-title":"Eur J Hum Genet"},{"issue":"7","key":"2139_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehs123.","journal-title":"Eur Heart J"},{"issue":"1","key":"2139_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","volume":"16","author":"D Adams","year":"2021","unstructured":"Adams D, Algalarrondo V, Polydefkis M, Sarswat N, Slama MS, Nativi-Nicolau J. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021;16(1):411. https:\/\/doi.org\/10.1186\/s13023-021-01960-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2139_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87(6):620\u20137. https:\/\/doi.org\/10.1136\/jnnp-2015-310907.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2139_CR15","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.1038\/s41598-021-91113-6","volume":"11","author":"MM Parker","year":"2021","unstructured":"Parker MM, Damrauer SM, Tcheandjieu C, et al. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Sci Rep. 2021;11(1):11645. https:\/\/doi.org\/10.1038\/s41598-021-91113-6.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"2139_CR16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/wco.0000000000000288","volume":"29","author":"Y Parman","year":"2016","unstructured":"Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3\u201313. https:\/\/doi.org\/10.1097\/wco.0000000000000288.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2139_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/humu.23669","volume":"40","author":"D Rowczenio","year":"2019","unstructured":"Rowczenio D, Quarta CC, Fontana M, et al. Analysis of the TTR gene in the investigation of amyloidosis: a 25-year single UK center experience. Hum Mutat. 2019;40(1):90\u20136. https:\/\/doi.org\/10.1002\/humu.23669.","journal-title":"Hum Mutat"},{"issue":"4","key":"2139_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512\u201326. https:\/\/doi.org\/10.1002\/ejhf.2140.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2139_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.21037\/atm-20-4636","volume":"9","author":"JB Cruz Rodriguez","year":"2021","unstructured":"Cruz Rodriguez JB, Tallaj JA. Narrative review of pharmacotherapy for transthyretin cardiac amyloid. Ann Transl Med. 2021;9(6):519. https:\/\/doi.org\/10.21037\/atm-20-4636.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2139_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Conceicao","year":"2019","unstructured":"Conceicao I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3\u20139. https:\/\/doi.org\/10.1080\/13506129.2018.1556156.","journal-title":"Amyloid"},{"issue":"24","key":"2139_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312. https:\/\/doi.org\/10.1161\/circulationaha.116.021612.","journal-title":"Circulation"},{"key":"2139_CR22","unstructured":"Royal College of Physicians, Royal College of Pathologists and British Society for Genetic Medicine. Consent and confidentiality in genomic medicine: Guidance on the use of genetic and genomic information in the clinic. 3rd edition. Report of the Joint Committee on Genomics in Medicine. RCP, RCPath and BSGM, London, 2019."},{"key":"2139_CR23","unstructured":"National Genomic Test Directory Testing Criteria for Rare and Inherited Disease October 2021. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/Rare-and-inherited-disease-eligibility-criteria-2021-22-v2.pdf. Accessed 07 Feb 2022."},{"issue":"4","key":"2139_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.20344\/amp.10526","volume":"32","author":"M Paneque","year":"2019","unstructured":"Paneque M, F\u00e9lix J, Mendes \u00c1, et al. Twenty years of a pre-symptomatic testing protocol for late-onset neurological diseases in Portugal. Acta Med Port. 2019;32(4):295\u2013304. https:\/\/doi.org\/10.20344\/amp.10526.","journal-title":"Acta Med Port"},{"issue":"3","key":"2139_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/famp.12306","volume":"57","author":"\u00c1 Mendes","year":"2018","unstructured":"Mendes \u00c1, Metcalfe A, Paneque M, Sousa L, Clarke AJ, Sequeiros J. Communication of information about genetic risks: putting families at the center. Fam Process. 2018;57(3):836\u201346. https:\/\/doi.org\/10.1111\/famp.12306.","journal-title":"Fam Process"},{"issue":"3","key":"2139_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mus.25210","volume":"54","author":"HH Schmidt","year":"2016","unstructured":"Schmidt HH, Barroso F, Gonz\u00e1lez-Duarte A, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2016;54(3):353\u201360. https:\/\/doi.org\/10.1002\/mus.25210.","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"2139_CR27","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27-35. https:\/\/doi.org\/10.1097\/WCO.0000000000000290.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2139_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","volume":"15","author":"M Grandis","year":"2020","unstructured":"Grandis M, Obici L, Luigetti M, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15(1):348. https:\/\/doi.org\/10.1186\/s13023-020-01633-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2139_CR29","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1038\/s41598-021-94650-2","volume":"11","author":"D Korthals","year":"2021","unstructured":"Korthals D, Chatzantonis G, Bietenbeck M, Meier C, Stalling P, Yilmaz A. CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci Rep. 2021;11(1):15521. https:\/\/doi.org\/10.1038\/s41598-021-94650-2.","journal-title":"Sci Rep"},{"issue":"1","key":"2139_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12687-017-0338-0","volume":"9","author":"A Lopes","year":"2018","unstructured":"Lopes A, Sousa A, Fonseca I, et al. Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study. J Community Genet. 2018;9(1):93\u20139. https:\/\/doi.org\/10.1007\/s12687-017-0338-0.","journal-title":"J Community Genet"},{"issue":"30","key":"2139_CR31","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"issue":"1","key":"2139_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/circulationaha.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/circulationaha.118.038169.","journal-title":"Circulation"},{"key":"2139_CR33","unstructured":"Sekijima Y. Hereditary transthyretin amyloidosis. 2001 Nov 5 [Updated 2021 Jun 17]. In: Adam MP, Ardinger HH, Pagon RA et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1194\/. Accessed 07 Feb 2022."},{"issue":"11","key":"2139_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.40.11.e120","volume":"40","author":"V Plante-Bordeneuve","year":"2003","unstructured":"Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003;40(11):e120. https:\/\/doi.org\/10.1136\/jmg.40.11.e120.","journal-title":"J Med Genet"},{"issue":"1","key":"2139_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","volume":"59","author":"MM Reilly","year":"1995","unstructured":"Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry. 1995;59(1):45\u20139. https:\/\/doi.org\/10.1136\/jnnp.59.1.45.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02139-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:36:33Z","timestamp":1653042993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02139-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}